Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.

@article{Ychou1999Individual5A,
  title={Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.},
  author={Marc Ychou and Jacqueline Duffour and Fr{\'e}d{\'e}ric Pinguet and Andrew Kramar and Jean M. Joulia and Delphine Topart and Françoise Bressolle},
  journal={Anticancer research},
  year={1999},
  volume={19 3B},
  pages={2229-35}
}
AIM OF THE STUDY SFU-dose adaptation optimal schedule using bimonthly LV5FU2 regimen was modulated by previously validated individual pharmacokinetic parameters, in 38 patients with advanced colorectal cancer. METHODS At the 1st cure, 5F-U pharmacokinetic parameters (particularly the area under curve (AUC) in mg.h/l.m2) were calculated in all patients. In 19 patients (A), 5FU infusion doses were progressively increased from 25 to 50% (at every cycle), according to AUC levels from 2nd to 6th… CONTINUE READING
6 Citations
0 References
Similar Papers